Appears in this Issue
Type A Dissections and Ascending Aortic Aneurysms
Abe DeAnda, MD1
John Ikonomidis, MD2; John Elefteriades, MD3
From the New York University School of Medicine1; Medical University of South Carolina, Charleston, SC2; Yale University School of Medicine, New Haven, CT3
- Date:July 7, 2011
- Article ID:CV9904
Dr. Abe DeAnda from the New York University School of Medicine moderated the topic "Type A Dissections and Ascending Aortic Aneurysms" with Drs. John Ikonomidis from the Medical University of South Carolina and John Elefteriades from the Yale University School of Medicine participating.
- The discussion focused primarily on:
- (1) aggressive targeting of low-density lipoprotein in high-risk patients;
- (2) the challenges of moving patients to an LDL cholesterol level <70 mg/dL, even with combination statin therapy;
- (3) the effect of results from recent trials such as AIM-HIGH and the recent warning on high-dose simvastatin on clinical practice;
- (4) the ideal LDL level in high-risk patients for primary or secondary prevention;
- (5) managing cholesterol levels in high-risk patients who cannot tolerate high-dose statins;
- (6) the potential impact of generic atorvastatin;
- (7) the role of risk scores such as Framingham on LDL goal for primary prevention;
- (8) the role of coronary calcium scores, hsCRP, and Lp(a) levels on management approaches;
- (9) the importance of non-HDL cholesterol and HDL cholesterol on risk and the implications for treatment; and
- (10) the impact of aggressive lifestyle approaches on raising HDL levels.
- (Med Roundtable Cardiovasc Ed. 2011;2(3):167-174) ©2011 FoxP2 Media, LLC
LOGIN to view full article
NEED INSTANT ACCESS?
Register Now for Your Free Digital Subscription!